Compare ASTE & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTE | CVAC |
|---|---|---|
| Founded | 1972 | 2000 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | 2020 |
| Metric | ASTE | CVAC |
|---|---|---|
| Price | $46.44 | $5.08 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $41.00 | $6.83 |
| AVG Volume (30 Days) | 176.9K | ★ 1.7M |
| Earning Date | 11-05-2025 | 11-24-2025 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | N/A | ★ 94.02 |
| EPS | ★ 2.08 | 0.94 |
| Revenue | ★ $1,368,800,000.00 | $83,000,117.00 |
| Revenue This Year | $8.19 | N/A |
| Revenue Next Year | $6.23 | $23.40 |
| P/E Ratio | $22.41 | ★ $5.39 |
| Revenue Growth | ★ 6.66 | N/A |
| 52 Week Low | $29.65 | $2.48 |
| 52 Week High | $50.83 | $5.72 |
| Indicator | ASTE | CVAC |
|---|---|---|
| Relative Strength Index (RSI) | 57.44 | 41.06 |
| Support Level | $43.77 | $5.05 |
| Resistance Level | $47.56 | $5.20 |
| Average True Range (ATR) | 1.57 | 0.14 |
| MACD | 0.45 | -0.01 |
| Stochastic Oscillator | 84.59 | 20.83 |
Astec Industries Inc designs and manufactures equipment and components used in road construction and other development activities. Its products are used through the entire process of building roads, from mining and crushing materials to creating the road surface. The company manufactures a line of plants, pavers, vehicles, and machines to mix and transform materials into construction components. It has two operating segments: infrastructure solutions generating maximum revenue and materials solutions. The majority of sales are derived from the United States. Its customers are asphalt producers, highway and heavy equipment contractors, ready mix concrete producers, demolition recycling markets, sand and gravel producers, open mine operators, quarry operators, and others.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.